Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. (HKG:1349)
Hong Kong
· Delayed Price · Currency is HKD 2.760
+0.050 (1.85%)
Apr 29, 2026, 4:08 PM HKT
HKG:1349 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Net Income | -157.44 | 39.73 | 108.63 | 138 | 213.3 | Upgrade
|
| Depreciation & Amortization | 61.03 | 74.2 | 59.93 | 80.97 | 60.85 | Upgrade
|
| Other Amortization | 17.62 | 8.02 | 2.3 | 1.22 | 0.96 | Upgrade
|
| Loss (Gain) From Sale of Assets | -0.22 | -0.03 | -0.3 | -1.92 | -1.78 | Upgrade
|
| Asset Writedown & Restructuring Costs | 0.35 | 4.42 | 5.78 | 1.01 | 0.35 | Upgrade
|
| Loss (Gain) From Sale of Investments | 9.85 | 10.41 | 4.35 | 1.28 | -20.76 | Upgrade
|
| Stock-Based Compensation | - | - | -1.84 | 7.69 | 64.97 | Upgrade
|
| Provision & Write-off of Bad Debts | -23.85 | -8.93 | 23.9 | -2.41 | 5.78 | Upgrade
|
| Other Operating Activities | 1.8 | 2.49 | 6.23 | -0.28 | -6.13 | Upgrade
|
| Change in Accounts Receivable | 213.27 | 114.05 | -10.47 | -89.73 | -95.37 | Upgrade
|
| Change in Inventory | 12.53 | -5.86 | -6.57 | -5.84 | 0.32 | Upgrade
|
| Change in Accounts Payable | 1.46 | -236.31 | -74.05 | 48.72 | 72.56 | Upgrade
|
| Change in Unearned Revenue | 3.13 | 13.69 | -31.89 | -6.76 | -9.89 | Upgrade
|
| Operating Cash Flow | 141.4 | -16.51 | 71.02 | 165.27 | 268.9 | Upgrade
|
| Operating Cash Flow Growth | - | - | -57.03% | -38.54% | 137.96% | Upgrade
|
| Capital Expenditures | -32.37 | -42.67 | -98.97 | -87.3 | -120.12 | Upgrade
|
| Sale of Property, Plant & Equipment | 0.83 | 0.64 | 0.68 | 1.44 | 1.71 | Upgrade
|
| Divestitures | - | - | - | - | 6.34 | Upgrade
|
| Investment in Securities | 15.25 | 18.15 | 52.91 | -10.88 | -243.6 | Upgrade
|
| Other Investing Activities | 4.08 | 1.74 | - | - | - | Upgrade
|
| Investing Cash Flow | -12.21 | -22.14 | -45.38 | -96.75 | -355.67 | Upgrade
|
| Short-Term Debt Issued | - | - | - | 101 | - | Upgrade
|
| Total Debt Issued | - | - | - | 101 | - | Upgrade
|
| Long-Term Debt Repaid | -6.81 | -7.93 | -109.38 | -9.52 | -7.5 | Upgrade
|
| Total Debt Repaid | -6.81 | -7.93 | -109.38 | -9.52 | -7.5 | Upgrade
|
| Net Debt Issued (Repaid) | -6.81 | -7.93 | -109.38 | 91.48 | -7.5 | Upgrade
|
| Issuance of Common Stock | - | - | 66.86 | - | - | Upgrade
|
| Repurchase of Common Stock | - | - | - | -8.7 | -40.82 | Upgrade
|
| Common Dividends Paid | -31.1 | -93.29 | -76.15 | -71.04 | -52.15 | Upgrade
|
| Other Financing Activities | - | -0.05 | -0.31 | -0.14 | -0.69 | Upgrade
|
| Financing Cash Flow | -37.91 | -101.27 | -118.98 | 11.61 | -101.16 | Upgrade
|
| Foreign Exchange Rate Adjustments | -0.49 | 0.32 | -0.07 | 0.29 | -0.07 | Upgrade
|
| Net Cash Flow | 90.79 | -139.61 | -93.41 | 80.42 | -188.01 | Upgrade
|
| Free Cash Flow | 109.03 | -59.18 | -27.95 | 77.96 | 148.78 | Upgrade
|
| Free Cash Flow Growth | - | - | - | -47.60% | 110.76% | Upgrade
|
| Free Cash Flow Margin | 15.90% | -8.34% | -3.29% | 7.56% | 13.05% | Upgrade
|
| Free Cash Flow Per Share | 0.10 | -0.06 | -0.03 | 0.08 | 0.14 | Upgrade
|
| Cash Income Tax Paid | 49.54 | 49.21 | 33.53 | 68.66 | 68.12 | Upgrade
|
| Levered Free Cash Flow | 153.42 | -96.46 | 18.64 | 86.7 | 116.02 | Upgrade
|
| Unlevered Free Cash Flow | 153.83 | -96.09 | 20.56 | 87.67 | 116.68 | Upgrade
|
| Change in Working Capital | 232.25 | -146.83 | -137.96 | -60.29 | -48.63 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.